Dongsung Pharm Total Liabilities
Dongsung Pharm total liabilities. Based on the latest financial reports, Dongsung Pharm (002210) has total liabilities worth ₩107.40 Billion KRW (≈ $72.78 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Dongsung Pharm (002210) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Dongsung Pharm (2008–2024)
Total liabilities of Dongsung Pharm from 2008 to 2024. This chart illustrates how Dongsung Pharm's total liabilities have evolved over time, based on quarterly financial data. Explore 002210 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Dongsung Pharm Competitors by Total Liabilities
The table below lists competitors of Dongsung Pharm ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Trailblazer Merger Corporation I Class A Common Stock
NASDAQ:TBMC
|
USA | $16.24 Million |
|
Vertex Minerals Ltd
AU:VTX
|
Australia | AU$11.34 Million |
|
Vunani Ltd
JSE:VUN
|
South Africa | ZAC1.57 Billion |
|
Bridger Aerospace Group Holdings, Inc. Common Stock
NASDAQ:BAER
|
USA | $289.84 Million |
|
MIND CTI Ltd
NASDAQ:MNDO
|
USA | $6.97 Million |
|
Alticast Corporation
KQ:085810
|
Korea | ₩30.34 Billion |
|
Global Vectra Helicorp Limited
NSE:GLOBALVECT
|
India | Rs8.96 Billion |
|
A.S. Création Tapeten AG
F:ACWN
|
Germany | €35.45 Million |
Liability Composition Analysis (2008–2024)
This chart breaks down Dongsung Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Dongsung Pharm.
Liquidity & Leverage Metrics
Dongsung Pharm Total Liabilities Ratios Explained
Dongsung Pharm total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dongsung Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dongsung Pharm (2008–2024)
The table below shows the annual total liabilities of Dongsung Pharm from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩96.73 Billion ≈ $65.56 Million |
+28.69% |
| 2023-12-31 | ₩75.17 Billion ≈ $50.94 Million |
+15.84% |
| 2022-12-31 | ₩64.89 Billion ≈ $43.98 Million |
+11.61% |
| 2021-12-31 | ₩58.14 Billion ≈ $39.40 Million |
-17.84% |
| 2020-12-31 | ₩70.77 Billion ≈ $47.96 Million |
+14.83% |
| 2019-12-31 | ₩61.63 Billion ≈ $41.77 Million |
-25.49% |
| 2018-12-31 | ₩82.71 Billion ≈ $56.05 Million |
+38.05% |
| 2017-12-31 | ₩59.91 Billion ≈ $40.60 Million |
-14.12% |
| 2016-12-31 | ₩69.77 Billion ≈ $47.28 Million |
+8.37% |
| 2011-12-31 | ₩64.38 Billion ≈ $43.63 Million |
-6.30% |
| 2010-12-31 | ₩68.71 Billion ≈ $46.56 Million |
+14.63% |
| 2009-12-31 | ₩59.94 Billion ≈ $40.62 Million |
+5.62% |
| 2008-12-31 | ₩56.75 Billion ≈ $38.46 Million |
-- |
About Dongsung Pharm
Dong Sung Bio Pharm.Co.,Ltd. manufactures and sells pharmaceuticals and cosmetics in South Korea. The company offers over the counter drugs, such as emollient, vitamin supplement, alopecia treatment, antihistamines, liver disease treatment, fire extinguisher solvent, antiviral, eye drops, menopause treatment, sleep inducer, antipyretic, analgesic, anti-inflammatory, vascular reinforcement, broad-… Read more